GlassScriptPhysician profile
Cora S King
NPI 1023654068
$5,259.68
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,010 · 2022: $1,255 · 2023: $477 · 2024: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $993.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,445.31 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $883.72 | 2021-2023 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $457.31 | 2021-2023 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $275.35 | 2021-2024 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.68 | 2021-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $206.26 | 2021-2022 | |
| Lilly USA, LLC | $204.16 | 2021-2024 | Jardiance, Emgality, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $145.50 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $145.06 | 2021 | |
| Amgen INC. | $144.02 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $120.00 | 2024 | Caplyta |
| Abbvie INC. | $113.41 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $104.24 | 2021-2022 | |
| Esperion Therapeutics, INC. | $100.97 | 2021 | |
| Janssen Pharmaceuticals, INC | $84.25 | 2021-2023 | Xarelto |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $70.83 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $66.12 | 2021-2022 | |
| Pfizer INC. | $65.55 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $60.80 | 2021-2022 | |
| Medtronic, INC. | $49.04 | 2021-2024 | Intellis Adaptivestim |
| Eisai INC. | $44.31 | 2021 | |
| Exact Sciences Corporation | $36.52 | 2023 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $25.14 | 2021 | |
| Mylan Specialty L.P. | $21.59 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.85 | 2022 | |
| Hikma Pharmaceuticals USA | $16.79 | 2021 | |
| Eyevance Pharmaceuticals LLC | $16.79 | 2021 | |
| Merck Sharp & Dohme LLC | $15.77 | 2022 | |
| Almatica Pharma LLC | $14.56 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.49 | 2022 | |
| Corcept Therapeutics | $13.52 | 2024 | Korlym |
| Kowa Pharmaceuticals America, INC. | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cora King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.